Market Indices
Sector Heatmap
GLP — Global Partners LP
NYSEGlobal Partners LP
- O
- 46.00
- H
- 47.45
- L
- 46.00
- V
- 24.16K
GLP — Latest News & Headlines
20 StoriesShould Value Investors Buy Global Partners (GLP) Stock? - Yahoo Finance
Should Value Investors Buy Global Partners (GLP) Stock? Yahoo Finance
5 Best GLP-1 Stocks for 2026 and How to Invest - The Motley Fool
5 Best GLP-1 Stocks for 2026 and How to Invest The Motley Fool
Health System Pharmacies Keep Patients on GLP-1 Therapy - AJMC
Health System Pharmacies Keep Patients on GLP-1 Therapy AJMC
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s - CNBC
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s CNBC
Global Partners (GLP) Cools After Recent Pullback, Is The Stock Still Cheap? - Simply Wall Street
Global Partners (GLP) Cools After Recent Pullback, Is The Stock Still Cheap? Simply Wall Street
GLP-1 Payment Risks: What Pharmacies Should Review with Their Processor - pharmaceuticalcommerce.com
GLP-1 Payment Risks: What Pharmacies Should Review with Their Processor pharmaceuticalcommerce.com
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 - Fierce Biotech
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 Fierce Biotech
GLP-1 users report more nail detachment, hair loss than nonusers, study finds - medicaleconomics.com
GLP-1 users report more nail detachment, hair loss than nonusers, study finds medicaleconomics.com
Global Partners (NYSE:GLP) Shares Pass Above 200-Day Moving Average - Should You Sell? - MarketBeat
Global Partners (NYSE:GLP) Shares Pass Above 200-Day Moving Average - Should You Sell? MarketBeat
Global Partners (GLP) Could Be 58% Undervalued On Its Cash Flow View - Yahoo Finance
Global Partners (GLP) Could Be 58% Undervalued On Its Cash Flow View Yahoo Finance
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? - The Motley Fool
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? The Motley Fool
How the GLP-1 Boom Stress-Tests the Pharma Cold Chain - pharmaceuticalcommerce.com
How the GLP-1 Boom Stress-Tests the Pharma Cold Chain pharmaceuticalcommerce.com
PepsiCo (PEP) Stock May Be 22% Undervalued On GLP 1 Risk - Simply Wall Street
PepsiCo (PEP) Stock May Be 22% Undervalued On GLP 1 Risk Simply Wall Street
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote - AJMC
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote AJMC
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? - Yahoo Finance
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? Yahoo Finance
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? The Motley Fool
VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results - Yahoo Finance
VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results Yahoo Finance
McDonald's is spending $8.5 billion to overhaul its menu for the GLP-1 era — and shares dropped 6% on the news - Yahoo Finance
McDonald's is spending $8.5 billion to overhaul its menu for the GLP-1 era — and shares dropped 6% on the news Yahoo Finance
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets - Yahoo Finance
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets Yahoo Finance
Will GLP-1s hurt food stocks? Assessing the changing consumer. - Yahoo Finance
Will GLP-1s hurt food stocks? Assessing the changing consumer. Yahoo Finance